Scientists Hope to Erase High Cholesterol for Life with Gene Editing

Scientists are making significant strides in gene-editing technology, hoping to offer a lifelong solution for high cholesterol. Recent breakthrough research involves a one-time gene-editing infusion designed to permanently modify specific genes in the liver that regulate cholesterol production. Early clinical trials have shown promising results, with therapies like VERVE-102 and CTX310 significantly reducing "bad" LDL cholesterol and triglycerides in patients whose conditions were resistant to standard medications.

These experimental treatments, utilizing technologies such as CRISPR-Cas9, target genes like PCSK9 and ANGPTL3 to effectively switch them off. In initial studies, participants experienced substantial and sustained reductions in LDL cholesterol, with some trials reporting decreases of up to 60-62% for LDL and around 50-55% for triglycerides, maintained for periods ranging from several months to over a year. This approach mimics natural genetic mutations found in individuals who inherently have very low cholesterol levels and a reduced risk of heart disease throughout their lives.

While these early-phase, first-in-human trials have demonstrated the therapies to be generally safe and effective in reducing harmful blood fats, researchers emphasize the need for larger and longer-term studies to confirm durability and fully assess long-term safety. If successful in broader populations, this "one-and-done" gene-editing strategy could revolutionize cardiovascular care, potentially eliminating the need for daily medication and offering permanent protection against heart disease.